Moreover, it has been reported that CDK2 inhibitor could augment the antiproliferative impact of lapatinib (ERBB2 inhibitor) in CCNE1/ERBB2 co-amplified GC cells77. This evidence concerns the gene CDK2 and gastric cancer.